Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Enfortumab Vedotin for High-Risk Upper Tract Urothelial Carcinoma
NCT05775471Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, enfortumab vedotin in upper tract urothelial carcinoma (UTUC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jun 2024; status: recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT05775471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775471.